Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R)-3-Hydroxybutanoate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | CPT1A | P50416 | 1/20 | 0.39 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-3-Hydroxybutanoate SCHEMBL22321678 | 1.00 | CA2 (0.57) | CA2CA4SLC22A16CA1CTSL | |
| (R)-3-Hydroxybutanoate SCHEMBL19459352 | 1.00 | CA2 (0.57) | CA2CA4SLC22A16CA1CTSL | |
| (R)-3-Hydroxybutanoate SCHEMBL21225057 | 0.97 | CA2 (0.55) | CA2CA4SLC22A16CA1CTSL | |
| (R)-3-Hydroxybutanoate SCHEMBL30390135 | 0.97 | CA2 (0.55) | CA2CA4SLC22A16CA1CTSL | |
| (R)-3-Hydroxybutanoate SCHEMBL20518506 | 0.94 | CA2 (0.57) | CA2CA4SLC22A16CA1CTSL | |
| (R)-3-Hydroxybutanoate SCHEMBL22321684 | 0.94 | — | — | |
| (R)-3-Hydroxybutanoate SCHEMBL194589 | 0.94 | — | — | |
| (R)-3-Hydroxybutanoate SCHEMBL1330790 | 0.94 | — | — | |
| (R)-3-Hydroxybutanoate SCHEMBL21060562 | 0.94 | CA2 (0.57) | CA2CA4SLC22A16CA1CTSL | |
| (R)-3-Hydroxybutanoate SCHEMBL7765391 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130876-A1 | ADMINISTRATION OF BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS | AXCESS GLOBAL SCIENCES LLC (US) | 2026-05-14 | — | — | US | claimed |
| US-12551455-B2 | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate | AXCESS GLOBAL SCIENCES, LLC (US) | 2026-02-17 | — | — | US | claimed |
| US-12496283-B2 | Administration of R-beta-hydroxybutyrate and related compounds in humans | AXCESS GLOBAL SCIENCES, LLC (US) | 2025-12-16 | — | — | US | claimed |
| US-20250280862-A1 | SOLUBLE KETONE SUPPLEMENTS AND APPLICATIONS | MINDFULL COMMUNITY INC (US) | 2025-09-11 | — | — | US | claimed |
| US-12396974-B2 | Ketone ester as a therapeutic treatment of Covid-19 and related viral infections | KetoneAid (US) | 2025-08-26 | — | — | US | claimed |
| CN-119968132-A | Acid and salt compound and preparation method thereof | 南京纽邦生物科技有限公司 | 2025-05-09 | — | — | CN | claimed |
| US-20250127736-A1 | BUTYRATE AND BETA-HYDROXYBUTYRATE COMPOSITIONS | CAVALERI FRANCO (CA) | 2025-04-24 | — | — | US | claimed |
| US-12251362-B2 | Administration of R-beta-hydroxybutyrate and related compounds in humans | AXCESS GLOBAL SCIENCES, LLC (US) | 2025-03-18 | — | — | US | claimed |
| US-20250032434-A1 | ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS | AXCESS GLOBAL SCIENCES, LLC | 2025-01-30 | — | — | US | claimed |
| CN-118543646-B | Process method for removing phosphorus from waste catalyst | 河北欣芮再生资源利用有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-107162893-A | (R) synthesis technique of 3 hydroxybutyric acids and its salt | 洛阳华荣生物技术有限公司 | 2017-09-15 | — | — | CN | claimed |
| US-20170258745-A1 | MIXED SALT COMPOSITIONS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | AXCESS GLOBAL SCIENCES, LLC | 2017-09-14 | — | — | US | claimed |
| WO-2017156446-A1 | MIXED SALT COMPOSITIONS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | ACCESS GLOBAL SCIENCES, LLC (US) | 2017-09-14 | — | — | WO | claimed |
| US-9675577-B2 | Compositions and methods for producing elevated and sustained ketosis | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-06-13 | — | — | US | claimed |
| US-20160067207-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-03-10 | — | — | US | claimed |
| EP-2976073-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | University Of South Florida (US) | 2016-01-27 | — | — | EP | claimed |
| US-9138420-B2 | Compositions and methods for producing elevated and sustained ketosis | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-09-22 | — | — | US | claimed |
| US-20140350105-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-11-27 | — | — | US | claimed |
| WO-2014153416-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-09-25 | — | — | WO | claimed |
| US-6613356-B1 | Medication for weight loss by means of appetite suppression and a method for administering this medication to humans and other mammals. The medication comprises potassium butyrate or closely related chemical compounds, together with chemicals | AXCESS GLOBAL SCIENCES, LLC | 2003-09-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551455-B2 | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate | KCNAB1, HADHB, BCKDK | CA2 148/4885CA4 497/4885SLC22A16 374/4885 |
| US-12496283-B2 | Administration of R-beta-hydroxybutyrate and related compounds in humans | HBB, SLC6A12, CYP8B1 | CA2 2746/4885CA4 3718/4885SLC22A16 25/4885 |
| US-20260130876-A1 | ADMINISTRATION OF BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS | HBB, SLC6A12, SLC6A6 | CA2 1488/4885CA4 3021/4885SLC22A16 32/4885 |
| US-20250032434-A1 | ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS | HBB, SLC6A12, CYP8B1 | CA2 2746/4885CA4 3718/4885SLC22A16 25/4885 |
| US-12396974-B2 | Ketone ester as a therapeutic treatment of Covid-19 and related viral infections | ACE, HSD17B13, IL1B | CA2 3794/4885CA4 2360/4885SLC22A16 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.